Yorktown Management & Research Company’s Catalyst Pharmaceutical CPRX Stock Holding History

Yorktown Management & Research Company’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$325K	Buy	+10,350	New	+$305K	0.2%	198
2025 Q4	–	Sell	-17,300	Closed	-$341K	–	224
2025 Q3	$341K	Hold	17,300	–	–	0.27%	152
2025 Q2	$375K	Sell	17,300 -20,250	-54%	-$478K	0.36%	124
2025 Q1	$911K	Hold	37,550	–	–	0.99%	10
2024 Q4	$784K	Hold	37,550	–	–	0.75%	26
2024 Q3	$746K	Buy	37,550 +17,300	+85%	+$321K	0.76%	28
2024 Q2	$314K	Sell	20,250 -20,250	-50%	-$315K	0.34%	145
2024 Q1	$646K	Hold	40,500	–	–	0.61%	42
2023 Q4	$681K	Hold	40,500	–	–	0.71%	36
2023 Q3	$473K	Hold	40,500	–	–	0.53%	58
2023 Q2	$544K	Sell	40,500 -9,500	-19%	-$137K	0.59%	55
2023 Q1	$829K	Hold	50,000	–	–	0.89%	16
2022 Q4	$930K	Hold	50,000	–	–	1.14%	11
2022 Q3	$642K	Hold	50,000	–	–	0.83%	22
2022 Q2	$351K	Buy	+50,000	New	+$367K	0.45%	99

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CIEC

Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

CWP

Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CNAM

Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return

Yorktown Management & Research Company's CPRX Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 10,350 shares worth $325K. The stake represents 0.2% of the portfolio and ranks #198 among its holdings. This is a return to the name: Yorktown Management & Research Company previously reported a position in CPRX as recently as Q3 2025.

Yorktown Management & Research Company first reported a position in CPRX in Q2 2022 and has held it in 15 quarters since. The position peaked at $930K in Q4 2022. 103 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Yorktown Management & Research Company held 10,350 shares of Catalyst Pharmaceutical worth $325K as of Q2 2026.
Catalyst Pharmaceutical was a new Yorktown Management & Research Company position in Q2 2026.
Catalyst Pharmaceutical made up 0.2% of Yorktown Management & Research Company's portfolio in Q2 2026, its #198 holding.
Yorktown Management & Research Company first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 15 quarters since.
Yorktown Management & Research Company's Catalyst Pharmaceutical position peaked at $930K in Q4 2022.
103 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.